Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $26.36, for a total value of $425,476.76. Following the transaction, the chief marketing officer owned 16,141 shares in the company, valued at $425,476.76. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE traded down $0.85 during midday trading on Thursday, hitting $25.87. The stock had a trading volume of 477,427 shares, compared to its average volume of 639,798. Maze Therapeutics, Inc. has a 1 year low of $14.16 and a 1 year high of $53.65. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $28.76 and a 200-day simple moving average of $31.34. The company has a market capitalization of $1.44 billion, a PE ratio of -10.27 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, sell-side analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. lifted its position in shares of Maze Therapeutics by 10.2% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares during the period. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $133,502,907. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. purchased a new stake in Maze Therapeutics in the second quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth $101,764,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MAZE shares. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.